The Centers for Medicare and Medicaid Services sent a letter to U.S. senator stating Mylan NV has been overcharging the U.S. for years on its EpiPen allergy shot by misclassifying the drug under Medicaid pricing rules. Read article here…..
Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.